Mirum Pharmaceuticals Earnings Call Transcripts
Fiscal Year 2026
-
Strong clinical and commercial momentum continues, with LIVMARLI sales growth, positive pivotal data in PSC, and pipeline expansion through disciplined BD. Upcoming milestones include key readouts for volixibat and Brelovitug, with significant market opportunities projected.
-
The event highlighted robust growth, a diversified rare disease pipeline, and strategic capital allocation. Key assets like LIVMARLI, volixibat, and brelovitug are expected to drive significant revenue, with multiple clinical readouts and regulatory milestones anticipated in the next year.
-
Q1 net product sales rose to $160M, driven by strong LIVMARLI uptake in PFIC and international markets. Full-year guidance increased to $660–$680M, with pipeline expansion into PSC, hepatitis delta, and FOP. Bluejay acquisition and Incyte licensing support future growth.
-
Volixibat achieved significant and clinically meaningful reduction in pruritus for PSC patients in the VISTAS phase II-B study, with a strong safety profile and robust efficacy across pruritus severities. AZURE-1 phase II-B brelovitug data in hepatitis delta also met primary endpoints, supporting upcoming regulatory filings.
-
Multiple pivotal data readouts and launches are expected over the next 18 months, with significant commercial growth projected from new indications and international expansion. Market development efforts and overlapping infrastructure will support launches, while business development remains a strategic focus.
-
Focused on rare disease medicines, the company projects $630-650 million in annual revenue and anticipates four pivotal clinical readouts in the next 18 months. LIVMARLI and volixibat are each positioned as billion-dollar brands, with strong commercial growth and a robust pipeline supporting future expansion.
-
Strong commercial growth and robust late-stage pipeline drive revenue guidance of $630M–$650M for 2024. Multiple pivotal trial readouts are expected in 2024–2025, with LIVMARLI and volixibat each targeting $1B+ peak sales and new market expansions underway.
-
Strong commercial growth and robust pipeline set the stage for a pivotal 18 months, with four major clinical readouts expected. Livmarli, Volixibat, and Brilovatug target significant rare disease markets, supported by durable revenue, expanding indications, and a well-financed outlook.
Fiscal Year 2025
-
Net product sales grew 55% year-over-year to $521 million in 2025, led by LIVMARLI and international expansion. Guidance for 2026 targets $630–$650 million in sales, with four pivotal clinical readouts expected and increased R&D investment, especially in brelovitug.
-
The acquisition adds a late-stage, high-potential therapy for hepatitis delta to the rare disease portfolio, leveraging strong phase II data and regulatory designations. The $620M deal, plus milestones, is expected to drive significant synergies, expand market reach, and accelerate value creation.
-
Three approved rare disease medicines are driving strong revenue and cash flow, with continued growth expected from both commercial products and a robust pipeline. The Fragile X program targets a billion-dollar market, while PSC and PBC trials advance with promising endpoints and manageable side effects.
-
Q3 revenue reached $133 million with positive net income, driven by strong growth in rare disease therapies and new product launches. Key clinical readouts for Volixibat and label expansions are expected in the next 18 months, while increased genetic testing is expanding the addressable market.
-
Q3 2025 saw 47% revenue growth to $133M, first-time positive net income, and strong U.S. and international sales, especially for LIVMARLI. Pipeline advances include pivotal readouts for Volixibat and MRM-3379, with full-year revenue guidance raised to $500–$510M.
-
Revenue guidance for 2025 was raised on strong growth from LIVMARLI and international markets. Key clinical milestones include pivotal readouts for volixibat in PSC and PBC, and a phase II start for 3379 in Fragile X syndrome. Focus remains on rare diseases and disciplined portfolio expansion.
-
Strong commercial growth is driven by LIVMARLI’s expanded indications and international rollout, with peak sales now expected to exceed $1 billion. The pipeline is advancing with pivotal studies in PSC and PBC, and a new Fragile X program, while strategic use of AI and global BD opportunities support future growth.
-
Revenue guidance was raised with cash flow positivity achieved, driven by strong product performance and robust Takeda partnership revenue. Market penetration for key products is growing, with a full pipeline and expanded clinical studies supporting future growth. Strategic focus remains on rare diseases and leveraging late-stage development and commercial strengths.
-
Q2 2025 revenue grew 64% year-over-year to $128 million, led by LIVMARLI and bile acid portfolio strength. Full-year guidance was raised to $490–$510 million, with continued U.S. and international expansion and a robust late-stage pipeline supporting future growth.
-
Livmarli posted record Q1 revenues and is nearing 50% U.S. market penetration for Alagille syndrome, with further growth expected in PFIC and international markets. Pipeline progress includes the EXPAND study, strong interim data for volixibat in PSC and PBC, and a new Fragile X program. IP protection extends to 2043 for key assets.
-
Record Q1 revenue of $111.6M marked 61% growth year-over-year, prompting a raised 2025 sales outlook to $435–$450M. Three major regulatory approvals and strong pipeline progress, including durable volixibat data, support continued momentum and financial strength.
-
2025 guidance targets $420–$435 million in revenue, led by LIVMARLI’s growth in Alagille syndrome and PFIC, with international expansion and new launches like CTEXLI supporting further gains. Pipeline progress in PSC and PBC, margin expansion, and a focus on rare disease assets underpin a strong outlook.
-
Revenue guidance for 2025 is $420–$435 million, driven by growth in rare disease medicines and international expansion. Key pipeline catalysts include Volixibat in PSC/PBC and the EXPAND study for Livmarli, with a new Fragile X asset entering phase 2.
Fiscal Year 2024
-
2024 saw robust sales growth, label expansions, and pipeline progress, with net product sales up 88% year-over-year and strong cash flow. 2025 guidance projects $420–$435 million in sales, continued profitability, and further pipeline catalysts.
-
Strong Q3 revenue and raised guidance reflect robust commercial performance and pipeline momentum. Key programs include Livmarli's EXPAND study, volixibat's progress in PBC/PSC, and a new Fragile X initiative with MRM-3379, all supported by positive interim data and strategic trial designs.
-
Record revenues and raised guidance reflect strong commercial execution, especially for Livmarli and the bile acid portfolio. Volixibat's phase IIb data in PBC and PSC show promise, while a new Fragile X candidate expands the pipeline.
-
Q3 2024 saw net product sales surge 89% year-over-year to $90.3 million, driven by strong U.S. and international growth in rare disease medicines. Full-year revenue guidance was raised to $330-$335 million, with pipeline advances including Volixibat's breakthrough designation and a new Fragile X program.
-
Strong commercial growth is driven by Livmarli's expanding U.S. and international presence, with new PFIC uptake and robust pricing in Europe. Pipeline progress includes the EXPAND trial and Volixibat's promising phase IIb data, while strategic focus remains on U.S. patient penetration and label expansion.
-
Strong commercial growth is projected, with Livmarli leading in rare cholestatic diseases and new label expansions underway. Volixibat's pivotal studies in PSC and PBC show promising interim results, while Chenodal's upcoming label expansion could unlock further market potential.
-
Q2 2024 saw 139% year-over-year sales growth to $77.8M, driven by strong performance across all products and key regulatory milestones. Positive interim results in volixibat studies and robust cash reserves support continued pipeline advancement.
-
Interim phase II-B results for volixibat in PSC and PBC showed rapid, significant pruritus reduction and favorable safety, with both studies advancing at the 20 mg b.i.d. dose. Improvements in fatigue and bile acids were also observed, supporting broad potential use and future NDA filings.
-
The company is advancing a portfolio of rare disease therapies, with LIVMARLI driving growth and label expansion, and new products like volixibat and bile acid replacements targeting larger and underserved markets. Strong financials and a robust pipeline support long-term growth ambitions.